View ValuationTrivarX 将来の成長Future 基準チェック /06現在、 TrivarXの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長22.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australiaお知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australiaお知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listingお知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australiaお知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、TrivarX は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:MDBI.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-2-3-1N/A9/30/20250-2-3-1N/A6/30/20251-1-20N/A3/31/20252-1-20N/A12/31/202420-20N/A9/30/20241-1-3-1N/A6/30/20241-1-4-1N/A3/31/20240-3-4-2N/A12/31/20230-4-5-2N/A9/30/20230-3-4-1N/A6/30/20231-3-3-1N/A3/31/20231-8-4-1N/A12/31/20221-12-4-2N/A9/30/20221-13-4-2N/A6/30/20221-13-5-2N/A3/31/20221-7-5-2N/A12/31/20211-1-4-1N/A9/30/20211-1-4-2N/A6/30/20211-1-4-2N/A3/31/20211-2-3-1N/A12/31/20201-2-3-1N/A9/30/20201-3-4-2N/A6/30/20201-4-5-4N/A3/31/20201-4-6-4N/A12/31/20191-5-7-5N/A9/30/20193-6N/A-6N/A6/30/20194-7N/A-7N/A3/31/20193-11N/A-10N/A12/31/20183-15N/A-13N/A9/30/20183-15N/A-13N/A6/30/20182-16N/A-12N/A3/31/20183-15N/A-10N/A12/31/20173-13N/A-8N/A9/30/20173-11N/A-7N/A6/30/20173-10N/A-5N/A3/31/20173-9N/A-4N/A12/31/20164-7N/A-2N/A9/30/20163-7N/A-2N/A6/30/20162-6N/A-3N/A3/31/20162-6N/A-3N/A12/31/20151-7N/A-2N/A9/30/20151-7N/A-2N/A6/30/20150-8N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MDBI.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MDBI.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MDBI.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MDBI.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MDBI.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MDBI.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:26終値2026/05/06 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TrivarX Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stuart RobertsPitt Street Research Pty Ltd.
お知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia
お知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia
お知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.
お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia
お知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.